These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21124771)

  • 1. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study.
    Shenoy C; Boura J; Orshaw P; Harjai KJ
    PLoS One; 2010 Nov; 5(11):e15070. PubMed ID: 21124771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-Label StenT (GHOST) Registry.
    Harjai KJ; Sattur S; Orshaw P; Boura J
    J Interv Cardiol; 2012 Feb; 25(1):28-36. PubMed ID: 21981467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry.
    Sattur S; Orshaw P; Boura J; Harjai KJ
    J Interv Cardiol; 2012 Apr; 25(2):118-25. PubMed ID: 22324820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group.
    Brodie BR; Stuckey T; Downey W; Humphrey A; Nussbaum M; Laurent S; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):893-900. PubMed ID: 19016465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
    Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major adverse cardiovascular events after drug-eluting stent implantation in patients with single chronic total occlusion: a single-center registry.
    Gilis-Siek N; Fijalkowski M; Jaguszewski M; Targonski R; Strozyk A; Cackowska M; Masiewicz E; Skarzynski P; Burakowski S; Chmielecki M; Lewicki L; Dubaniewicz W; Gruchala M; Ciecwierz D; Rynkiewicz A
    J Invasive Cardiol; 2013 Nov; 25(11):567-72. PubMed ID: 24184890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
    Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
    J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients.
    Minha S; Bental T; Assali A; Vaknin-Assa H; Lev EI; Rechavia E; Battler A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Nov; 78(5):710-7. PubMed ID: 21805561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting versus bare-metal stents in large coronary arteries of patients with ST-segment elevation myocardial infarction: findings from the ICAS registry.
    Abe D; Sato A; Hoshi T; Maruta S; Misaki M; Kakefuda Y; Watabe H; Hiraya D; Sakai S; Kawabe M; Takeyasu N; Aonuma K
    J Cardiol; 2014 Nov; 64(5):377-83. PubMed ID: 24685689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety.
    Prasad SB; David T; Malaiapan Y; Cameron JD; Meredith IT
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):193-200. PubMed ID: 20549694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.